ORCA Therapeutics to Present at the European Association for Cancer Research Congress

Amsterdam, The Netherlands – June 2024

AMSTERDAM, The Netherlands – Prof. Dr. Victor W. van Beusechem will deliver an oral presentation at the European Association for Cancer Research (EACR) Congress, which will be held from June 10-13, 2024, in Rotterdam, The Netherlands.

The presentation, titled “Oncolytic Adenovirus ORCA-010 Activates the Tumor Microenvironment and Induces Systemic Tumor-Specific T Cell Responses in Patients with Newly-Diagnosed Prostate Cancer,” will highlight key findings from ORCA Therapeutics’ clinical study.

Prof. Dr. Victor W. van Beusechem, Chief Scientific Officer of ORCA Therapeutics and presenter of the study, expressed his enthusiasm: “We are excited to present our latest updated findings on ORCA-010 at the EACR Congress. Our research demonstrates the potential of ORCA-010 to significantly alter the tumor microenvironment and initiate robust, systemic anti-tumor immune responses. These results represent a significant step forward in our efforts to develop effective oncolytic virus-based therapies for cancer.”

The presentation will provide insights into the mechanism of ORCA-010, its ability to induce activation of the tumor microenvironment and elicit tumor-specific T cell responses. Together these findings support the development of ORCA-010 for patients with newly-diagnosed prostate cancer. ORCA Therapeutics is dedicated to advancing innovative cancer treatments and looks forward to engaging with the scientific community at EACR to discuss these promising results.

For more information about the EACR Congress, please visit the EACR website.

For further information and media inquiries, please contact:

Dr. Wenliang Dong, Ph.D. MBA
Email: wen.dong@orca-therapeutics.com
Website: www.orca-therapeutics.com

About ORCA Therapeutics BV: ORCA Therapeutics BV is a clinical stage biopharmaceutical company dedicated to developing oncolytic immunotherapies for cancer treatment. With a focus on innovative gene therapies, ORCA Therapeutics is committed to improving patient outcomes and addressing unmet medical needs. Learn more at www.orca-therapeutics.com.